Chen Chenglong, Wang Shidong, Wang Juan, Yao Fangzhou, Tang Xiaodong, Guo Wei
Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, People's Republic of China.
Department of Orthopedics, Beijing Jishuitan Hospital, Beijing, People's Republic of China.
APL Bioeng. 2023 Feb 23;7(1):011501. doi: 10.1063/5.0137026. eCollection 2023 Mar.
Despite recent developments worldwide in the therapeutic care of osteosarcoma (OS), the ongoing challenges in overcoming limitations and side effects of chemotherapy drugs warrant new strategies to improve overall patient survival. Spurred by rapid progress in biomedicine, nanobiotechnology, and materials chemistry, chemotherapeutic drug delivery in treatment of OS has become possible in recent years. Here, we review recent advances in the design of drug delivery system, especially for chemotherapeutic drugs in OS, and discuss the relative merits in trials along with future therapeutic options. These advances may pave the way for novel therapies requisite for patients with OS.
尽管近年来全球范围内骨肉瘤(OS)的治疗护理取得了进展,但在克服化疗药物的局限性和副作用方面仍面临挑战,这需要新的策略来提高患者的总体生存率。受生物医学、纳米生物技术和材料化学快速发展的推动,近年来在骨肉瘤治疗中进行化疗药物递送已成为可能。在此,我们综述了药物递送系统设计的最新进展,特别是骨肉瘤化疗药物的递送系统,并讨论了试验中的相对优点以及未来的治疗选择。这些进展可能为骨肉瘤患者所需的新疗法铺平道路。